The calmodulin-binding transcription activator 1 (CAMTA1) antibody is a crucial tool for studying the CAMTA1 protein, a member of the CAMTA family of transcription factors. CAMTA1 contains conserved domains, including CG-1 DNA-binding, TIG-like, ankyrin repeats, and IQ calmodulin-binding motifs, enabling its role in calcium/calmodulin-mediated transcriptional regulation. It is broadly expressed in the brain, heart, and muscles, and functions in neuronal development, cell cycle control, and stress responses.
CAMTA1 is implicated in cancer biology, particularly in tumors like epithelioid hemangioendothelioma and meningioma, where chromosomal rearrangements or aberrant expression are observed. Antibodies targeting CAMTA1 are widely used in techniques such as Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to detect protein expression, localization, and post-translational modifications. They aid in exploring CAMTA1's tumor-suppressive or oncogenic roles, depending on context.
Additionally, CAMTA1 mutations are linked to cerebellar ataxia and neurodevelopmental disorders. Validated CAMTA1 antibodies (polyclonal/monoclonal) are essential for diagnostic pathology and research, helping clarify its interactions with signaling pathways (e.g., TGF-β, MAPK) and potential therapeutic targets. Proper validation via knockout controls ensures specificity, given homology with CAMTA2. Overall, CAMTA1 antibodies are pivotal in understanding its dual roles in physiology and disease.